FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC

Lung Cancer Considered
27/05/2025 33 min
FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC

Listen "FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC"

Descargar episodio Ver en sitio original

Episode Synopsis

In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA